Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14784934 | 0.83 | POLB (0.39) | TSHRHTTPOLBCYP19A1PGR | |
| SCHEMBL18433800 | 0.83 | LMNA (0.32) | LMNA | |
| SCHEMBL19220255 | 0.83 | LMNA (0.35) | LMNA | |
| SCHEMBL15649642 | 0.81 | MAPT (0.42) | TSHRHTTPOLBCYP19A1PGR | |
| SCHEMBL17164402 | 0.79 | MEN1 (0.43) | TSHRHTTPOLBCYP19A1MAPT | |
| SCHEMBL13722908 | 0.79 | CYP1A2 (0.44) | TSHRHTTPOLBCYP19A1MAPT | |
| SCHEMBL18703862 | 0.79 | MAPT (0.50) | TSHRHTTPOLBCYP19A1MAPT | |
| SCHEMBL16327649 | 0.78 | CYP19A1 (0.41) | TSHRHTTPOLBCYP19A1PGR | |
| SCHEMBL15719607 | 0.78 | LMNA (0.44) | TSHRHTTPOLBMAPTMEN1 | |
| SCHEMBL14785329 | 0.78 | CXCR4 (0.34) | TSHRHTTPOLBCYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368129-B | Modified macrocyclic compounds | 拜耳医药股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| CN-107001341-B | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group | 拜耳医药股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-3126338-B1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP | Bayer Pharma AG (DE) | 2019-09-04 | — | — | EP | disclosed |
| EP-3207037-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3207037-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180282346-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | US | disclosed |
| EP-3207038-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | Bayer Pharma AG (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-9962389-B2 | 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| US-9962389-B2 | 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| EP-2699554-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2013037896-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037896-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037894-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037894-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012160034-A1 | 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012160034-A1 | 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012143399-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | PAH, NAT1, H1-5 | TSHR 1255/4885HTT 564/4885POLB 236/4885 |
| US-20180282346-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | PCNA, CYP11B2, CYP11B1 | TSHR 2618/4885HTT 2333/4885POLB 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.